DPYD Polyclonal Antibody, 20ul Multiplex Immunoassays Designed for seamless integration with

Designed for seamless integration with centrifuge tubes

A second transferrin receptor

ANKRD30A is a differentiation antigen and a potential target for antibody‐based therapies in breast cancers

Mutations in DCLRE1C can cause Athabascan-type severe combined immunodeficiency (SCIDA) and Omenn syndrome

featuring a high capacity of 50 kDa

DPYD Polyclonal Antibody, 20ul Multiplex Immunoassays Designed for seamless integration withDihydropyrimidine dehydrogenase [NADP(+)] encoded by DPYD is a pyrimidine catabolic enzyme and the initial and rate limiting factor in the pathway of uracil and thymidine catabolism. Mutations in this gene result in dihydropyrimidine dehydrogenase deficiency, an error in pyrimidine metabolism associated with thymine uraciluria and an increased risk of toxicity in cancer patients receiving 5 fluorouracil chemotherapy. Two transcript variants encoding